Leerink Partners analyst Joseph Schwartz has maintained their neutral stance on SRPT stock, giving a Hold rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Schwartz has given his Hold rating due to a combination of factors surrounding Sarepta Therapeutics’ recent strategic decisions. The company decided to sell its entire stake in Arrowhead Pharmaceuticals, which Schwartz views as a prudent move to strengthen the balance sheet. However, the sale was made at a significant discount, raising concerns about the company’s financial stability and its ability to meet future obligations, such as the 2027 convertible note.
Additionally, Schwartz is cautious about the implications of the upcoming siRNA data expected in the second half of 2025. While the company maintains confidence in its siRNA approach and the work being done by Arrowhead, the timing of the sale and the potential impact of the data release create uncertainty. This combination of financial maneuvers and pending data results contributes to the Hold rating, as further developments are needed to justify a more positive outlook.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $20.00 price target.
SRPT’s price has also changed dramatically for the past six months – from $107.950 to $20.300, which is a -81.19% drop .